<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p21" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_21{left:130px;bottom:1195px;letter-spacing:0.22px;}
#t2_21{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_21{left:128px;bottom:1095px;letter-spacing:-0.21px;}
#t4_21{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_21{left:128px;bottom:1042px;letter-spacing:0.16px;}
#t6_21{left:238px;bottom:1043px;letter-spacing:-0.07px;}
#t7_21{left:141px;bottom:1008px;letter-spacing:-0.1px;}
#t8_21{left:250px;bottom:1009px;letter-spacing:-0.01px;}
#t9_21{left:143px;bottom:952px;letter-spacing:-0.29px;}
#ta_21{left:253px;bottom:972px;letter-spacing:-0.01px;}
#tb_21{left:253px;bottom:952px;letter-spacing:-0.01px;}
#tc_21{left:253px;bottom:924px;letter-spacing:-0.01px;}
#td_21{left:253px;bottom:904px;letter-spacing:-0.01px;}
#te_21{left:253px;bottom:885px;letter-spacing:-0.01px;}
#tf_21{left:253px;bottom:866px;letter-spacing:-0.01px;}
#tg_21{left:253px;bottom:837px;letter-spacing:-0.01px;}
#th_21{left:250px;bottom:782px;letter-spacing:-0.04px;}
#ti_21{left:238px;bottom:737px;letter-spacing:-0.01px;}
#tj_21{left:238px;bottom:718px;letter-spacing:-0.01px;}
#tk_21{left:238px;bottom:698px;letter-spacing:-0.01px;}
#tl_21{left:238px;bottom:679px;letter-spacing:-0.01px;}
#tm_21{left:238px;bottom:625px;letter-spacing:-0.01px;}
#tn_21{left:238px;bottom:605px;letter-spacing:-0.01px;}
#to_21{left:238px;bottom:586px;letter-spacing:-0.01px;}
#tp_21{left:238px;bottom:532px;letter-spacing:-0.01px;}
#tq_21{left:238px;bottom:512px;letter-spacing:-0.01px;}
#tr_21{left:238px;bottom:493px;letter-spacing:-0.01px;}
#ts_21{left:638px;bottom:493px;letter-spacing:-0.01px;}
#tt_21{left:660px;bottom:493px;letter-spacing:-0.01px;}
#tu_21{left:238px;bottom:473px;letter-spacing:-0.01px;}
#tv_21{left:238px;bottom:454px;letter-spacing:-0.01px;}
#tw_21{left:238px;bottom:435px;letter-spacing:-0.01px;}
#tx_21{left:238px;bottom:415px;letter-spacing:-0.01px;}
#ty_21{left:238px;bottom:361px;letter-spacing:-0.01px;}
#tz_21{left:238px;bottom:342px;letter-spacing:-0.01px;}
#t10_21{left:238px;bottom:322px;letter-spacing:-0.01px;}
#t11_21{left:238px;bottom:303px;letter-spacing:-0.01px;}
#t12_21{left:238px;bottom:249px;letter-spacing:-0.01px;}
#t13_21{left:238px;bottom:229px;letter-spacing:-0.01px;}
#t14_21{left:238px;bottom:210px;letter-spacing:-0.01px;}
#t15_21{left:238px;bottom:190px;letter-spacing:-0.01px;}
#t16_21{left:238px;bottom:136px;letter-spacing:-0.01px;}
#t17_21{left:238px;bottom:117px;letter-spacing:-0.01px;}
#t18_21{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_21{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_21{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_21{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_21{font-size:26px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_21{font-size:21px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_21{font-size:20px;font-family:NotoSans-Regular_7j-;color:#000;}
.s6_21{font-size:14px;font-family:NotoSans-Regular_7j-;color:#000;}
.s7_21{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s8_21{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
.s9_21{font-size:13px;font-family:NotoSans-Regular_7j-;color:#F78C00;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts21" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg21Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg21" style="-webkit-user-select: none;"><object width="908" height="1286" data="21/21.svg" type="image/svg+xml" id="pdf21" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_21" class="t s0_21">3.1. Prevalence/ Incidence </span><span id="t2_21" class="t s1_21">21 </span>
<span id="t3_21" class="t s2_21">3. </span><span id="t4_21" class="t s3_21">Epidemiology </span>
<span id="t5_21" class="t s4_21">3.1. </span><span id="t6_21" class="t s5_21">Prevalence/ Incidence </span>
<span id="t7_21" class="t s6_21">3.1. </span><span id="t8_21" class="t s7_21">Consensus-based statement </span>
<span id="t9_21" class="t s2_21">EEC </span>
<span id="ta_21" class="t s7_21">The estimated crude incidence rate for laryngeal cancer for 2016 is 8.0 per 100,000 in men </span>
<span id="tb_21" class="t s7_21">and 1.4 per 100,000 in women. </span>
<span id="tc_21" class="t s7_21">Since 2000, the incidence of laryngeal cancer has decreased significantly in younger men. </span>
<span id="td_21" class="t s7_21">A slight decrease has also been observed in older men. During the same period, the </span>
<span id="te_21" class="t s7_21">incidence rate in women has remained constant. The mortality rates have decreased in </span>
<span id="tf_21" class="t s7_21">both sexes. </span>
<span id="tg_21" class="t s7_21">The average age of onset is 64 years for women and 66 years for men. </span>
<span id="th_21" class="t s8_21">Strong consensus: 95% </span>
<span id="ti_21" class="t s7_21">Laryngeal carcinoma is the third most common malignant tumor in the head and neck region </span>
<span id="tj_21" class="t s7_21">after oral cavity and pharyngeal carcinoma. The age-standardized incidence rate in Germany in </span>
<span id="tk_21" class="t s7_21">2012 was 5.4 per 100,000 for men and 1.0 per 100,000 for women. Currently, around 3100 men </span>
<span id="tl_21" class="t s7_21">and 490 women are newly diagnosed with laryngeal carcinoma each year [2]. </span>
<span id="tm_21" class="t s7_21">The gender ratio in Germany is approximately 7:1 [3]. One in 170 men will develop laryngeal </span>
<span id="tn_21" class="t s7_21">cancer during their lifetime, whereas only one in 1,100 women will develop it [4]. The 5-year </span>
<span id="to_21" class="t s7_21">prevalence in 2012 was 11,400 cases for men and 1,800 cases for women [4]. </span>
<span id="tp_21" class="t s7_21">In international comparison, the incidence and mortality rate in Germany is behind countries </span>
<span id="tq_21" class="t s7_21">such as Poland and France, but ahead of countries such as Finland and Sweden. The incidence </span>
<span id="tr_21" class="t s7_21">rate depends in particular on the risk factor smoking (see chapter</span><span id="ts_21" class="t s9_21">3.2 </span><span id="tt_21" class="t s7_21">). In the European Union, </span>
<span id="tu_21" class="t s7_21">mortality remained almost constant between 1980 and 1991, but since 1991 there has been an </span>
<span id="tv_21" class="t s7_21">annual decline in mortality of 3.3% per year [5, 6]. Age-standardized mortality in the EU </span>
<span id="tw_21" class="t s7_21">decreased in one decade from 4.7 (1990-91) to 2.5 (2010-11) [5]. In the USA, the incidence and </span>
<span id="tx_21" class="t s7_21">mortality for laryngeal cancer have also decreased in the last 2 decades. </span>
<span id="ty_21" class="t s7_21">According to estimates by GLOBOCAN, more than 150,000 new cases of laryngeal carcinoma </span>
<span id="tz_21" class="t s7_21">occurred in men and more than 20,000 in women worldwide in 2015. In men, laryngeal </span>
<span id="t10_21" class="t s7_21">carcinoma is the 14th most common malignant tumor worldwide [7]. The global incidence of </span>
<span id="t11_21" class="t s7_21">laryngeal carcinoma is 5.1/100,000 for men and 0.6/100,000 for women [8]. </span>
<span id="t12_21" class="t s7_21">The frequency of laryngeal carcinoma in the defined sublocations is 17-23% for supraglottic </span>
<span id="t13_21" class="t s7_21">carcinomas, 75-80% for glottic carcinomas and 2-5% for subglottic carcinomas [3]. In a recent </span>
<span id="t14_21" class="t s7_21">analysis of German cancer registry data, glottic carcinomas accounted for 50% of newly </span>
<span id="t15_21" class="t s7_21">occurring laryngeal carcinomas in men and 33% in women [9]. </span>
<span id="t16_21" class="t s7_21">At the initial diagnosis of laryngeal carcinoma, the T-category T1 was 42% in men, T2 was 21%, </span>
<span id="t17_21" class="t s7_21">T3 was 20% and T4 was 17%, and in women the T-category T1 was 38%. </span>
<span id="t18_21" class="t s0_21">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
